ストックスクリーナーアプリを入手
5.51
1.44%
-0.11
前日終値:
$5.62
開ける：
$5.57
24時間の取引高:
127.70K
Relative Volume:
0.06
時価総額：
$1.12B
収益：
-
当期純損益:
$-54.70M
株価収益率:
-16.70
EPS:
-0.33
ネットキャッシュフロー:
$-51.36M
1週間 パフォーマンス:
-7.22%
1か月 パフォーマンス:
+7.35%
6か月 パフォーマンス:
+48.90%
1年 パフォーマンス:
+113.05%
1日の値動き範囲:
$5.50
$5.655
1週間の範囲:
$5.51
$6.145
52週間の値動き範囲:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.50 | 1.14B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.29 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.18 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
730.02 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.68 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-11-13 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-11-07 | 開始されました | Guggenheim | Buy |
| 2023-05-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
| 2021-03-16 | 開始されました | Piper Sandler | Overweight |
| 2021-03-15 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 再開されました | ROTH Capital | Neutral |
| 2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-09-27 | 再開されました | ROTH Capital | Buy |
| 2017-09-22 | 開始されました | Jefferies | Buy |
| 2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
Savara Inc. Confirms Participation in 2026 Citizens Life Sciences Conference Focused on Rare Respiratory Diseases - geneonline.com
Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MyChesCo
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application - simplywall.st
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears - MarketBeat
SVRA PE Ratio & Valuation, Is SVRA Overvalued - Intellectia AI
Savara, Inc. (SVRA) Investor Outlook: An 81% Upside Potential In Rare Respiratory Disease Treatment - DirectorsTalk Interviews
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citizens reiterates Savara stock rating on likely FDA approval - Investing.com Nigeria
Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)? - simplywall.st
Savara Grants Inducement Equity Awards to New Employee - MyChesCo
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com - Investing.com India
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews
Savara (SVRA) Gains Priority Review for Molbreevi by FDA - GuruFocus
FDA accepts Savara’s drug application for rare lung disease - Investing.com India
Savara's Molbreevi BLA for Autoimmune Pulmonary Alveolar Proteinosis Accepted for FDA Review - marketscreener.com
Savara (SVRA) Gains FDA Priority Review for Molbreevi BLA - GuruFocus
FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA - GuruFocus
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - The AI Journal
FDA accepts Savara’s drug application for rare lung disease By Investing.com - Investing.com UK
Chart Watch: Whats the fair value of Savara Inc stockStop Loss & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach - TipRanks
GSA Capital Partners LLP Has $1.33 Million Stock Holdings in Savara Inc. $SVRA - MarketBeat
Major Savara Inc. (SVRA) holder reports 6.1% stake in Schedule 13G/A - Stock Titan
Savara (SVRA) Is Up 7.1% After BLA Resubmission And Pricing Reveal For Lead aPAP TherapyHas The Bull Case Changed? - simplywall.st
Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit - MarketBeat
Risk Check: Whats the fair value of Savara Inc stockQuarterly Earnings Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
What dividend safety score for Savara Inc. stockEarnings Growth Report & Safe Entry Point Identification - mfd.ru
SVRA Should I Buy - Intellectia AI
Savara Announces New Employment Inducement Grant - The Joplin Globe
Savara (NASDAQ:SVRA) Shares Up 6.8%Here's Why - MarketBeat
Should I set a stop loss on Savara Inc.Dividend Hike & Stepwise Entry/Exit Trade Alerts - mfd.ru
Growth Value: Is Savara Inc being accumulated by smart moneyEarnings Trend Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Savara Insiders Added US$535.6k Of Stock To Their Holdings - Yahoo Finance
Savara Secures Path to $150M as FDA Decision Nears for Rare Lung Drug - MyChesCo
Savara Announces Participation in Upcoming February 2026 Investor Healthcare Conferences - BioSpace
Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara (NASDAQ:SVRA) Trading 2.5% HigherShould You Buy? - MarketBeat
Expanded Hercules Credit Line Tied To MOLBREEVI Approval Could Be A Game Changer For Savara (SVRA) - simplywall.st
ETF Watch: Why is Savara Inc stock going downQuarterly Performance Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Savara grants equity awards to new hires as it advances rare lung drug - MSN
Growth Report: Is Savara Inc being accumulated by smart moneyQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Movement Recap: Will Savara Inc announce a stock splitStock Surge & AI Enhanced Execution Alerts - baoquankhu1.vn
Savara, Inc. (SVRA) Investor Outlook: Analyst Ratings Signal A Potential 93.77% Upside - DirectorsTalk Interviews
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI - BioSpace
Savara secures additional $75m in debt financing for potential drug launch - Investing.com Australia
Hercules Capital Ties Savara Funding To FDA Milestone And Valuation Case - simplywall.st
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
Savara Inc (SVRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | Director |
Dec 19 '25 |
Sale |
6.06 |
20,000 |
121,220 |
2,533,642 |
0.50%
大文字化:
|
ボリューム (24 時間):